tbuckley/cabot-search huggingface dataset:
Ubiquitously Expressed Micro RNA miR-16 Is Not Mutated and Not Differentially Expressed in Patients with B-CLL.
Authors: Pablo Landgraf, Uta Fuchs, Astrid Novosel, Valerio Fulci, Claudia Schoch, Torsten Haferlach, Raymund Buhmann, Thomas Tuschl, Arndt Borkhardt
Journal: Blood (2006)
Therapies and outcomes of non-renal cell carcinoma (non-RCC) neoplasms of the kidney: A single-institution experience.
Authors: Marc Ryan Matrana, Priya Rao, Bradley J. Atkinson, Charles Guo, Nizar M. Tannir
Journal: Journal of Clinical Oncology (2012)

431 Background: Non-RCC neoplasms of the kidney include neuroendocrine tumors (small cell carcinoma and carcinoid) and Primitive Neuroectodermal Tumors (PNET). Small cell carcinoma and renal carcinoids are small blue cell tumors that rarely occur as primary renal neoplasms. PNET, known as extraskeletal Ewing sarcoma, is characterized by t(11;22), the gold standard for diagnosis. It is a small round cell tumor derived from the neural crest and treated with chemotherapy; the role of nephrectomy is unclear. Methods: We reviewed records of patients seen at MDACC between 01/01/2001 and 01/01/2011 for PNET, small cell carcinomas, and carcinoid tumors of the kidney. Overall survival (OS) was determined from diagnosis to death. Results: 21 pts met inclusion criteria. Disease-specific data is shown in the table. Common treatments included: carboplatin/etoposide for small cell carcinomas; vincristine/doxorubicin/ifosfamide, vincristine/doxorubicin/cyclophosphamide, and doxorubicin/ifosfamide alternating with cisplatin/etoposide for PNET. Irinotecan was a common salvage agent in PNET. Most carcinoid tumors were treated with surgery alone. Two patients with small cell received whole brain radiation for brain metastases. Conclusions: Carcinoid tumors of the kidney had better outcomes compared to renal small cell carcinomas or PNET. Local carcinoid tumors of the kidney were generally managed with surgery alone. Renal small cell carcinomas and PNET were treated with systemic therapies. [Table: see text]
Therapeutic Benefit of Decitabine, a Hypomethylating Agent, in Patients with Myeloproliferative Neoplasm in Blastic Phase/Acute Myeloid Leukemia (MPN-AML), Accelerated Phase (MPN-AP), and DIPSS-Plus High Risk Primary Myelofibrosis (PMF)
Authors: Talha Badar, Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Jorge E. Cortes, Naveen Pemmaraju, Sherry R. Pierce, Naval Daver, Srdan Verstovsek
Journal: Blood (2014)
Consolidation Therapy Based on Conventional Chemotherapy and Corticoids Do Not Provide Therapeutic Advantage for Newly Diagnosed Patients after Autologous Transplantation.
Authors: Roman Hajek Prof, Ivan Spicka, Vlastimil Scudla, Evzen Gregora, Vladimir Maisnar, Miroslava Schutzova, Elena Tothova Prof, Martin Mistrik, Marta Krejci, Jan Straub, Jiri Minarik, Jakub Radocha, Vladimir Koza, Petr Pavlicek, Libuse Novosadova, Hana Frankova, Yvetta Stavarova, Petr Kessler, Lenka Walterova, Jaromir Gumulec, Adam Svobodnik, Dana Kralova, Zdenek Adam
Journal: Blood (2007)
Adjunctive Catheter-Directed Venous Thrombolysis in Iliofemoral Deep Vein Thrombosis; Short-Term Results from the CaVenT Study, a Multicenter Randomized Controlled Trial
Authors: Tone Rønnaug Enden, Carl-Erik Slagsvold, Nils-Einar Kløw, Per Morten Sandset
Journal: Blood (2008)
Prognostic Value of C-Reactive Protein, Lactase Dehydrogenase and Anemia in Recurrent or Refractory Malignant Lymphoma,
Authors: Kazuhito Suzuki, Yasuhito Terui, Yuko Mishima, Eriko Nara, Kenji Nakano, Kyoko Ueda, Noriko Nishimura, Sakura Sakajiri, Masahiro Yokoyama, Shunji Takahashi, Kiyohiko Hatake
Journal: Blood (2011)
Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (<scp><i>IGHV</i></scp> mutational status and <scp>FISH</scp> cytogenetics) separates patients with different outcome and simplifies the <scp>CLL‐IPI</scp>
Authors: Julio Delgado, Michael Doubek, Tycho Baumann, Jana Kotaskova, Stefano Molica, Pablo Mozas, Alfredo Rivas‐Delgado, Fortunato Morabito, Sarka Pospisilova, Emili Montserrat
Journal: American Journal of Hematology (2017)

Rai and Binet staging systems are important to predict the outcome of patients with chronic lymphocytic leukemia (CLL) but do not reflect the biologic diversity of the disease nor predict response to therapy, which ultimately shape patients' outcome. We devised a biomarkers-only CLL prognostic system based on the two most important prognostic parameters in CLL (i.e., IGHV mutational status and fluorescence in situ hybridization [FISH] cytogenetics), separating three different risk groups: (1) low-risk (mutated IGHV + no adverse FISH cytogenetics [del(17p), del(11q)]); (2) intermediate-risk (either unmutated IGHV or adverse FISH cytogenetics) and (3) high-risk (unmutated IGHV + adverse FISH cytogenetics). In 524 unselected subjects with CLL, the 10-year overall survival was 82% (95% CI 76%-88%), 52% (45%-62%), and 27% (17%-42%) for the low-, intermediate-, and high-risk groups, respectively. Patients with low-risk comprised around 50% of the series and had a life expectancy comparable to the general population. The prognostic model was fully validated in two independent cohorts, including 417 patients representative of general CLL population and 337 patients with Binet stage A CLL. The model had a similar discriminatory value as the CLL-IPI. Moreover, it applied to all patients with CLL independently of age, and separated patients with different risk within Rai or Binet clinical stages. The biomarkers-only CLL prognostic system presented here simplifies the CLL-IPI and could be useful in daily practice and to stratify patients in clinical trials.
Safety and Efficacy of a Combination of 5-Azacitidine Followed by Lenalidomide in High-Risk MDS or AML Patients with Del(5q) Cytogenetic Abnormalities – Results of the “AZALE” Trial,
Authors: Uwe Platzbecker, Christina Ganster, Jürgen Neesen, Andrea Kuendgen, Katharina Götze, Gesine Bug, Katayoon Shirneshan, Friederike Braulke, Christoph Röllig, Ralph Naumann, Eckhard Büssemaker, Aristoteles Giagounidis, Wolf-Karsten Hofmann, Ulrich Germing, Detlef Haase, Gerhard Ehninger
Journal: Blood (2011)
Single Agent Gemtuzumab Ozogamicin (Mylotarg) Can Induce Hematologic Remissions in Patients with Refractory Acute Myelogenous Leukemia (AML) Relapse Following Allogeneic Stem Cell Transplantation but May Precipitate Acute Graft-Versus-Host Disease (GVHD).
Authors: Mounzer E. Agha, Anastasios Raptis, Sarah B. Miller, Michelle Taylor, Markus Y. Mapara
Journal: Blood (2005)
“TF-kB”-Dependent Suppression of Agonist-Mediated Tissue Factor Induction by Histone Deacetylase Inhibitors in Human Endothelial Cells and Monocytes.
Authors: Jianguo Wang, Shawn A. Mahmud, Peter B. Bitterman, Yuqing Huo, Arne Slungaard
Journal: Blood (2006)
Killed but Metabolically Active Recombinant Listeria monocytogenes as an Antigen Delivery and Activation Platform for Human Dendritic Cell-Based Cancer Immunotherapy.
Authors: Dirk G. Brockstedt, Mojca Skoberne, Alice Yewdall, Keith S. Bahjat, Larry Corash, Thomas W. Dubensky, Nina Bhardwaj
Journal: Blood (2004)
Cystatin C is associated with mitral annular calcification in elderly adults: Results from the cardiovascular health study
Authors: Folkert W. Asselbergs, Dariush Mozaffarian, Ronit Katz, Bryan Kestenbaum, Linda F. Fried, John S. Gottidener, Michael G. Shlipak, David S. Siscovick
Journal: Circulation (2007)
Biochemical basis for activation of virulence genes by bile salts in<i>Vibrio parahaemolyticus</i>
Authors: Giomar Rivera-Cancel, Kim Orth
Journal: Gut Microbes (2017)

Bile salts act as a stressor to bacteria that transit the intestinal tract. Enteric pathogens have hijacked bile as an intestinal signal to regulate virulence factors. We recently demonstrated that Vibrio parahemolyticus senses bile salts via a heterodimeric receptor formed by the periplasmic domains of inner-membrane proteins VtrA and VtrC. Crystal structures of the periplasmic complex reveal that VtrA and VtrC form a β-barrel that binds bile salts in its hydrophobic interior to activate the VtrA cytoplasmic DNA-binding domain. Proteins with the same domain arrangement as VtrA and VtrC are widespread in Vibrio and related bacteria, where they are involved in regulating virulence and other unknown functions. Here we discuss our findings and review current knowledge on VtrA and VtrC homologs. We propose that signaling by these membrane-bound transcription factors can be advantageous for the regulation of membrane and secretory proteins.
Phase II Study of the Histone Deacetylase Inhibitor Panabinostat (LBH589) in Patients with Low or Intermediate-1 Risk Myelodysplastic syndrome
Authors: Sophie Dimicoli, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Zeev Estrov, Hui Yang, Mary A Kelly, Sherry Pierce, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2011)
Correlation of germline <i>MET</i> mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644).
Authors: Ramaprasad Srinivasan, Donald P. Bottaro, Toni K. Choueiri, Ulka N. Vaishampayan, Jonathan E. Rosenberg, Theodore Logan, Andrea Lynne Harzstark, Brian I. Rini, Sandy Srinivas, Laurel M. Adams, Kevin Laubscher, Lone Harild Ottesen, David F. McDermott, W. Marston Linehan
Journal: Journal of Clinical Oncology (2012)

372 Background: Activating mutations and/or amplifications in MET have been described in patients (pts) with papillary renal cell carcinoma (PRC). Foretinib, an oral multi-kinase inhibitor targeting MET, VEGF, RON, AXL, and TIE-2 receptors, was evaluated in a phase 2 study in pts with PRC. An important objective of this study was to evaluate whether activation of the MET receptor pathway by mutation, amplification, or gain of chromosome 7 was predictive for or correlated with clinical outcomes. Methods: Pts were stratified based on status of MET pathway activation. Blood samples were collected at screening for determination of germline MET mutational status. Archival tumor tissue samples were obtained for the analysis of somatic MET mutation, amplification of the MET locus (7q31), and gain of chromosome 7 using standardized assays. Results: A total of 74 pts were enrolled on the trial (37 each in intermittent and daily dosing arms); overall efficacy and safety data are reported separately at this meeting. Sixty-seven pts were evaluable for both mutation status and response. 5/10 pts (50%) with a germline MET mutation experienced a PR, while 5 pts (50%) had SD as their best response, including 4 pts who demonstrated tumor SLD reductions of &gt; 10%, but did not achieve PR by RECIST 1.0. Responses were also seen in pts without germline MET mutation. However, the presence of a germline MET mutation was highly predictive of a response as only 5/57 pts (9%) without a mutation experienced a PR. Other measures of MET pathway activation did not appear to correlate with activity with only 1/5 pts (20%) with somatic MET mutation having a PR; furthermore, in the absence of a concomitant MET mutation, no responses were seen in patients with MET amplification (n=2) and only 1/18 (5%) pts with a gain of chromosome 7 experienced a PR. Conclusions: The presence of germline MET mutations correlated strongly with activity of the MET inhibitor foretinib in pts with PRC. These data provide early proof of principle that MET may be a valid therapeutic target in a subset of patients with PRC.
Characterization of Double BCR-ABL–positive Cell Lines Established from a Patient with Blasic Crisis of Chronic Myeloid Leukemia Who Showed Clinical Resistant to Imatinib
Authors: Tsuyoshi Nakamaki, Norimichi Hattori, Hidetoshi Nakashima, Takashi Maeda, Hirotsugu Ariizumi, Shigeru Tomoyasu
Journal: Blood (2008)
CD34+ Circulating Progenitor Cell Frequency Is Highly Heritable
Authors: Kenneth S. Cohen, Susan Cheng, Martin G. Larson, L. Adrienne Cupples, Elizabeth L. McCabe, Ying A. Wang, Roderick P. Martin, Rachael J. Klein, Basma Hashmi, Christopher J. O'Donnell, Vasan S. Ramachandran, Stanley Y. Shaw, Thomas J. Wang
Journal: Blood (2010)
A Multinational Arab Genome‐Wide Association Study Identifies New Genetic Associations for Rheumatoid Arthritis
Authors: Richa Saxena, Robert M. Plenge, Andrew C. Bjonnes, Hassan S. Dashti, Yukinori Okada, Wessam Gad El Haq, Mohammed Hammoudeh, Samar Al Emadi, Basel K. Masri, Hussein Halabi, Humeira Badsha, Imad W. Uthman, Lauren Margolin, Namrata Gupta, Ziyad R. Mahfoud, Marianthi Kapiri, Soha R. Dargham, Grace Aranki, Layla A. Kazkaz, Thurayya Arayssi
Journal: Arthritis & Rheumatology (2017)

Genetic factors underlying susceptibility to rheumatoid arthritis (RA) in Arab populations are largely unknown. This genome-wide association study (GWAS) was undertaken to explore the generalizability of previously reported RA loci to Arab subjects and to discover new Arab-specific genetic loci.The Genetics of Rheumatoid Arthritis in Some Arab States Study was designed to examine the genetics and clinical features of RA patients from Jordan, the Kingdom of Saudi Arabia, Lebanon, Qatar, and the United Arab Emirates. In total, >7 million single-nucleotide polymorphisms (SNPs) were tested for association with RA overall and with seropositive or seronegative RA in 511 RA cases and 352 healthy controls. In addition, replication of 15 signals was attempted in 283 RA cases and 221 healthy controls. A genetic risk score of 68 known RA SNPs was also examined in this study population.Three loci (HLA region, intergenic 5q13, and 17p13 at SMTNL2/GGT6) reached genome-wide significance in the analyses of association with RA and with seropositive RA, and for all 3 loci, evidence of independent replication was demonstrated. Consistent with the findings in European and East Asian populations, the association of RA with HLA-DRB1 amino acid position 11 conferred the strongest effect (P = 4.8 × 10-16 ), and a weighted genetic risk score of previously associated RA loci was found to be associated with RA (P = 3.41 × 10-5 ) and with seropositive RA (P = 1.48 × 10-6 ) in this population. In addition, 2 novel associations specific to Arab populations were found at the 5q13 and 17p13 loci.This first RA GWAS in Arab populations confirms that established HLA-region and known RA risk alleles contribute strongly to the risk and severity of disease in some Arab groups, suggesting that the genetic architecture of RA is similar across ethnic groups. Moreover, this study identified 2 novel RA risk loci in Arabs, offering further population-specific insights into the pathophysiology of RA.
TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.
Authors: James Chih-Hsin Yang, Sanjay Popat, Panos Georgiou, Emiko Miyamoto, Jeffrey D. Isaacson, Heather A. Wakelee
Journal: Journal of Clinical Oncology (2015)

TPS8109 Background: Rociletinib is a small molecule inhibitor that selectively targets mutant EGFR and has been shown in preclinical studies to inhibit L858R, del19 and T790M while sparing wild-type EGFR. TIGER-X, a phase 1/2 dose-ranging trial, has provided evidence that rociletinib is associated with durable response and is well tolerated in pts with NSCLC and positive T790M status following progression on a TKI.1 TIGER-3 is designed to investigate single agent rociletinib vs chemotherapy in pts who have failed EGFR therapy and platinum-based doublet chemotherapy; a setting of acquired resistance and a high unmet need of targeted therapeutic options. TIGER-3 will evaluate pts with T790M positive and negative status based on blood and tumor tissues, and biomarkers of response or resistance. Methods: Pts with histologically or cytologically confirmed metastatic or unresectable locally advanced NSCLC, with radiological progression on the most recent therapy will be enrolled in a phase 3, randomized, open-label study (NCT02322281). Pts must have documented evidence of a tumor with ≥ 1 EGFR activating mutations excluding exon 20 insertion, and prior treatment with an EGFR TKI and platinum-containing doublet chemotherapy. Pts will be randomized 1:1 to receive rociletinib twice daily or single agent cytotoxic chemotherapy (investigator choice specified before randomization) until disease progression according to RECIST 1.1. Pts will be stratified by presence or absence of brain metastases, ECOG performance status (0 vs 1), and race (Asian vs non-Asian). The primary endpoint is progression-free survival (PFS). Secondary endpoints include objective response rate, duration of response, disease control rate, and overall survival. Kaplan-Meier methodology will assess time to event variables. The stratified log-rank and the hazard ratio (HR) will be used for comparing PFS distributions. Serial assessment of safety will be carried out based on standard adverse event reporting. Planned enrolment is 600 pts with study start planned by end of May 2015. Sequist LV J Clin Oncol. 2014 Clinical trial information: NCT02322281.
Use of Intrathecal Liposomal Cytarabine (DepoCyte) as Treatment of Lymphomatous Meningitis.
Authors: Nicola Cascavilla, Carlo Bodenizza, Angelo Michele Carella, Matteo Dell’Olio, Antonietta Falcone, Michele Mario Greco, Antonio La Sala, Saverio Mantuano, Lorella Melillo, Emanuela Merla, Michele Nobile, Grazia Sanpaolo, Potito Scalzulli
Journal: Blood (2006)
Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents.
Authors: Albero Rocci, Francesca Gay, Livio Trusolino, Paola Omedè, Andrea Bertotti, Vittorio Montefusco, Claudia Crippa, Francesca Patriarca, Milena Gilestro, Anna M. Liberati, Fausto Rossini, Tommaso Caravita, Antonietta Falcone, Giuseppe Rossi, Daniela Drandi, Paolo Corradini, Marco Ladetto, Paolo M. Comoglio, Mario Boccadoro, Antonio Palumbo
Journal: Blood (2009)
A Phase I Study of Alemtuzumab Dosing for Steroid-Refractory Chronic Graft-Versus-Host Disease
Authors: Sarah Nikiforow, Haesook T Kim, Bhavjot Bindra, Sean McDonough, Brett Glotzbecker, Philippe Armand, John Koreth, Vincent T Ho, Edwin P Alyea, Jerome Ritz, Robert J. Soiffer, Joseph H. Antin, Corey Cutler
Journal: Blood (2012)
Alternating Bortezomib and Dexamethasone as Induction Regimen Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Younger Patients with Multiple Myeloma: Results of a PETHEMA Phase II Trial.
Authors: Laura Rosinol, Albert Oriol, M. -Victoria Mateos, Anna Sureda, Joaquin Diaz-Mediavilla, Adrian Alegre, Juan-Jose Lahuerta, Javier De La Rubia, Carlos Herrero, Helgi Van de Velde, J. F. San Miguel, Joan Blade
Journal: Blood (2006)
Association of Hemolysis with Clinical Manifestations of Sickle Cell Disease
Authors: Mehdi Nouraie, Caterina Minniti, Craig Sable, Andrew D. Campbell, Sohail R Rana, Gregory Ensing, Niti Dham, Onyinye C. Onyekwere, Deepika S. Darbari, Gregory J. Kato, Mark Gladwin, Oswaldo Castro, Victor R. Gordeuk
Journal: Blood (2008)
The SH-SY5Y cell line in Parkinson’s disease research: a systematic review
Authors: Helena Xicoy, Bé Wieringa, Gerard J.M. Martens
Journal: Molecular Neurodegeneration (2017)

Parkinson's disease (PD) is a devastating and highly prevalent neurodegenerative disease for which only symptomatic treatment is available. In order to develop a truly effective disease-modifying therapy, improvement of our current understanding of the molecular and cellular mechanisms underlying PD pathogenesis and progression is crucial. For this purpose, standardization of research protocols and disease models is necessary. As human dopaminergic neurons, the cells mainly affected in PD, are difficult to obtain and maintain as primary cells, current PD research is mostly performed with permanently established neuronal cell models, in particular the neuroblastoma SH-SY5Y lineage. This cell line is frequently chosen because of its human origin, catecholaminergic (though not strictly dopaminergic) neuronal properties, and ease of maintenance. However, there is no consensus on many fundamental aspects that are associated with its use, such as the effects of culture media composition and of variations in differentiation protocols. Here we present the outcome of a systematic review of scientific articles that have used SH-SY5Y cells to explore PD. We describe the cell source, culture conditions, differentiation protocols, methods/approaches used to mimic PD and the preclinical validation of the SH-SY5Y findings by employing alternative cellular and animal models. Thus, this overview may help to standardize the use of the SH-SY5Y cell line in PD research and serve as a future user's guide.
Cell Cycle Features and Quantitative Alteration of Target Molecules of Malignant B Cells Treated with Inotuzumab Ozogamicin (CMC544) Alone or in Combination with Rituximab.
Authors: Nozomi Yamakage, Akihiro Takeshita, Kaori Shinjo, Takaaki Ono, Hirotaka Matsui, Satoki Nakamura, Kazuyuki Shigeno, Masato Maekawa, Kazunori Ohnishi, Ryuzo Ohno
Journal: Blood (2007)
Myeloid-Derived Suppressor Phenotype of Leukemic Blasts in Association with Increased Suppressor T Cell Subsets in Acute Myelogenous Leukemia– Evidence for Immunoediting.
Authors: Sawa Ito, Stephen A. Strickland, Bipin N. Savani, J. Joseph Melenhorst, Fang Yin, Pawel Muranski, Nancy F. Hensel, Fariba Chinian, Keyvan Keyvanfar, Christopher S. Hourigan, Minoo Battiwalla, A. John Barrett
Journal: Blood (2012)
PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
Authors: Jun Wang, Ruirong Yuan, Wenru Song, Jingwei Sun, Delong Liu, Zihai Li
Journal: Journal of Hematology & Oncology (2017)

The current success of targeted inhibition against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and Programmed Death 1/Programmed Death Ligand 1 (PD-1/PD-L1, herein collectively referred to as PD) pathways is hailed as a cancer immunotherapy breakthrough. PD-L1, known also as B7 homolog 1 (B7-H1), was initially discovered by Dr. Lieping Chen in 1999. To recognize the seminal contributions by Chen to the development of PD-directed therapy against cancer, the Chinese American Hematologist and Oncologist Network (CAHON) decided to honor him with its inaugural Lifetime Achievement Award in Hematology and Oncology at the CAHON's 2015 annual meeting. This essay chronicles the important discoveries made by Chen in the exciting field of immuno-oncology, which goes beyond his original fateful finding. It also argues that PD-directed therapy should be appropriately considered as Tumor-Site Immune Modulation Therapy to distinguish it from CTLA-4-based immune checkpoint blocking agents.
The Combination of Cyclophosphamide-Bortezomib-Dexamethasone (CYBOR-D) Is a Highly Effective and Well Tolerated Regimen that Produces Rapid and Complete Hematological Response In Patients with AL Amyloidosis
Authors: Joseph R. Mikhael, Steven R. Schuster, Victor H Jimenez-Zepeda, Nancy Bello, Jacy Spong, Craig B. Reeder, A. Keith Stewart, P.Leif Bergsagel, Rafael Fonseca
Journal: Blood (2010)
Long-Term Overall Survival In Diffuse Large B-Cell Lymphoma With Bone Marrow Involvement Patients After High-Dose Chemotherapy Plus Autologous Stem Cells Transplantation
Authors: Olga A. Gavrilina, Evgeny E. Zvonkov, Nelly G. Gabeeva, Eduard G. Gemdjian, Vladimir I. Vorobyev, Sergey K. Kravchenko, Valeri G. Savchenko
Journal: Blood (2013)